ARTICLE | Clinical News
Lipomel: Began Phase II trial
April 24, 2000 7:00 AM UTC
Biovector Therapeutics S.A., Toulouse, France Product: Lipomel Business: Cancer Therapeutic category: Immune stimulation Target: Immune cells Description: Therapeutic vaccine using the MART melanoma ...